About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Cladribine Tablets as an Exit Therapy Strategy

NCT06887426·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University Hospital, Strasbourg, France

Age

45–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patient ≥45-year-old with RRMS
Disease duration ≥10 years
No evidence of disease activity ≥5 years under DMT
EDSS score between 0 and 6.0 included

You may not be if

Progressive form of MS
Patients without DMT
EDSS score ≥6.5

The record

StatusCompleted

PhaseNo phase

Taking part450

StartedOct 2025

UpdatedOct 6, 2026

Conditions

Multiple Sclerosis Relapsing Remitting Multiple Sclerosis Secondary Progressive Multiple Sclerosis

Where1

Service de neurologie - Hôpitaux Universitaires de Strasbourg
Strasbourg, France

Clareo Health | Cladribine Tablets as an Exit Therapy Strategy